

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Peter Irwin Rubinstein
<b>Date of last notice</b>	1 November 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	RIP Opportunities Pty Ltd <PIR Super Fund A/C>
<b>Date of change</b>	20 December 2019

---

+ See chapter 19 for defined terms.

<b>No. of securities held prior to change</b>	<p><b>Irwin Biotech Nominees P/L &lt;BIO A/C&gt;</b> 6,200,000 ordinary shares</p> <p><b>Irwin Biotech Nominees Pty Ltd &lt;BIO A/C&gt;</b> 80,849,310 ordinary shares 5,000,000 Performance Rights</p> <p><b>Irwin Biotech Nominees Pty Ltd</b> 2,000,000 ordinary shares</p> <p><b>Irwin Biotech Nominees Pty Ltd</b> 26,582,700 ordinary shares (represented by 44,305 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd</b> 7,500,000 ordinary shares (represented by 12,500 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd &lt;PIR Super Fund A/C&gt;</b> 124,999,999 ordinary shares</p>
<b>Class</b>	Unlisted options with an exercise price of \$0.008 per option, expiring 29 October 2022 (Unlisted Options).
<b>Number acquired</b>	125,000,000 Unlisted Options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

<b>No. of securities held after change</b>	<p><b>Irwin Biotech Nominees P/L &lt;BIO A/C&gt;</b> 6,200,000 ordinary shares</p> <p><b>Irwin Biotech Nominees Pty Ltd &lt;BIO A/C&gt;</b> 80,849,310 ordinary shares 5,000,000 Performance Rights</p> <p><b>Irwin Biotech Nominees Pty Ltd</b> 2,000,000 ordinary shares</p> <p><b>Irwin Biotech Nominees Pty Ltd</b> 26,582,700 ordinary shares (represented by 44,305 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd</b> 7,500,000 ordinary shares (represented by 12,500 American Depositary Receipts)</p> <p><b>RIP Opportunities Pty Ltd &lt;PIR Super Fund A/C&gt;</b> 124,999,999 ordinary shares 125,000,000 Unlisted Options</p>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Unlisted Options issued pursuant to the sub-underwriting of non-renounceable rights issue as approved by shareholder under Resolution 6 at the Company's Annual General Meeting held on 28 November 2019.</p>

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Sub-underwriting Agreement
<b>Nature of interest</b>	Indirect
<b>Name of registered holder (if issued securities)</b>	RIP Opportunities Pty Ltd <PIR Super Fund A/C> Irwin Biotech Nominees Pty Ltd <BIO A/C>
<b>Date of change</b>	20 December 2019

+ See chapter 19 for defined terms.

Appendix 3Y  
Change of Director's Interest Notice

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Agreement to be issued, subject to shareholder approval, 125,000,000 unlisted options with an exercise price of \$0.008 per option, each option exercisable for one fully paid ordinary share in the Company at any time up to and including 5pm on 29 October 2022.
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	Agreement to be issued, subject to shareholder approval, 125,000,000 unlisted options with an exercise price of \$0.008 per option, each option exercisable for one fully paid ordinary share in the Company at any time up to and including 5pm on 29 October 2022.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Issued in part consideration for sub-underwriting of the Company's Non-Renounceable Rights.
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: Genetic Technologies Limited</b>
<b>ABN: 17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Jerzy Muchnicki
<b>Date of last notice</b>	1 November 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<b>JGM Investment Group (The Muchnicki Family A/C)</b>
<b>Date of change</b>	20 December 2019
<b>No. of securities held prior to change</b>	<b>MJGD Nominees Pty Ltd</b> 207,103,424 ordinary shares  <b>JGM Investment Group (The Muchnicki Family A/C)</b> 9,400,000 ordinary shares  <b>MJGD Nominees Pty Ltd (BSMI A/C)</b> 4,849,129 ordinary shares 6,250,000 Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y  
Change of Director's Interest Notice

<b>Class</b>	Unlisted options with an exercise price of \$0.008 per option, expiring 29 October 2022 (Unlisted Options).
<b>Number acquired</b>	125,000,000 Unlisted Options
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	<b>MJGD Nominees Pty Ltd</b> 207,103,424 ordinary shares  <b>JGM Investment Group (The Muchnicki Family A/C)</b> 9,400,000 ordinary shares 125,000,000 Unlisted Options  <b>MJGD Nominees Pty Ltd (BSMI A/C)</b> 4,849,129 ordinary shares 6,250,000 Performance Rights
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Unlisted Options issued pursuant to the sub-underwriting of non-renounceable rights issue as approved by shareholder under Resolution 6 at the Company's Annual General Meeting held on 28 November 2019.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Sub-underwriting Agreement
<b>Nature of interest</b>	Indirect
<b>Name of registered holder (if issued securities)</b>	MJGD Nominees Pty Ltd
<b>Date of change</b>	20 December 2019

+ See chapter 19 for defined terms.

<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Agreement to be issued, subject to shareholder approval, 125,000,000 unlisted options with an exercise price of \$0.008 per option, each option exercisable for one fully paid ordinary share in the Company at any time up to and including 5pm on 29 October 2022.
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	Agreement to be issued, subject to shareholder approval, 125,000,000 unlisted options with an exercise price of \$0.008 per option, each option exercisable for one fully paid ordinary share in the Company at any time up to and including 5pm on 29 October 2022.
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Issued in part consideration for sub-underwriting of the Company's Non-Renounceable Rights.
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

+ See chapter 19 for defined terms.